Can donor immune cells boost lung cancer remission?

NCT ID NCT07759856

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial is for people with extensive-stage small cell lung cancer who have completed initial chemotherapy plus immunotherapy and have stable or improved disease. Participants are randomly assigned to receive either standard immunotherapy alone or immunotherapy combined with infusions of natural killer (NK) cells from healthy donors. The goal is to see if adding NK cells can help keep the cancer from growing longer and improve overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Allogeneic natural killer (NK) cells from healthy donors, given as intravenous infusions alongside standard immunotherapy (immune checkpoint inhibitors).
What this could lead to
If adding donor NK cells to standard immunotherapy works, it could extend the time before extensive-stage small cell lung cancer progresses, potentially improving survival.
What could go wrong
This is an early-phase exploratory trial with a small number of participants, so results may not be conclusive. NK cell infusions can cause side effects, and the added benefit over immunotherapy alone is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tianjin First Central Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, 300192, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.